Application of G9a inhibitor in preparation of medicine for treating peripheral T cell lymphoma
The G9a inhibitor CM272 induces oxidative stress response at specific concentrations, solving the problem of high recurrence rates in PTCL treatment, achieving significant PTCL cell killing and tumor suppression effects, providing a new strategy for the clinical treatment of PTCL.
CN120459101APending Publication Date: 2025-08-12JIANGSU PROVINCE HOSPITAL (THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY)
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- CN202510957242.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-07-11
- Publication Date
- 2025-08-12
AI Technical Summary
Technical Problem
The current treatment of peripheral T-cell lymphoma (PTCL) has a high recurrence rate, with a 5-year overall survival rate of less than 30%. Targeted drugs have failed to significantly improve the prognosis, and there is a lack of effective novel therapeutic strategies.
Method used
PTCL cells were treated with G9a inhibitor CM272 within a specific concentration range (0.01~1μM). By inducing oxidative stress response, ROS accumulation and necrotic apoptosis were achieved, and the killing effect on PTCL cells was achieved.
Benefits of technology
CM272 significantly inhibits PTCL cell proliferation, reduces cell viability, promotes cell necrotic apoptosis, and significantly inhibits tumor growth in in vivo models, providing new drug choices for the treatment of PTCL.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN120459101A_ABST
Abstract
The invention discloses an application of a G9a inhibitor in preparation of a medicine for treating peripheral T cell lymphoma. The G9a inhibitor is CM272. The G9a inhibitor can effectively kill PTCL cells in a specific concentration range, the killing effect of the G9a inhibitor shows drug concentration dependence, and the higher the concentration of the G9a inhibitor is, the better the killing effect is. The action mechanism of the G9a inhibitor in peripheral T cell lymphoma is that PTCL cells are induced to generate oxidative stress reaction, ROS accumulation of the PTCL cells is promoted, necroptosis related protein expression is increased, and then necroptosis is caused. Experiments verify that the G9a inhibitor can effectively kill PTCL cells and inhibit the growth of the PTCL cells from in vitro and in vivo levels. The invention provides a new treatment scheme for clinical treatment of the peripheral T cell lymphoma, and improves the treatment effect on the peripheral T cell lymphoma.
Need to check novelty before this filing date? Find Prior Art